Hutchinson validates StO2 monitor in trauma setting:
This article was originally published in Clinica
Executive Summary
Hutchinson Technology says that a clinical trial has confirmed the value of using its noninvasive InSpectra tissue oxygen saturation (StO2) monitor in trauma patients. Local StO2 measured by the near infrared spectroscopy-based monitor on the muscle at the base of the thumb was a statistically significant indicator of inadequate blood flow in trauma patients, revealed the study of 383 severely injured people. InSpectra was cleared for sale in the US in July this year. Shipments of the device are expected to begin by the end of 2006, says the Hutchinson, Minnesota firm. The technology is indicated for use in monitoring patients during circulatory or perfusion examinations of skeletal muscle, or when there is a suspicion of compromised circulation.